Yohann Loriot, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the results of a Phase II trial (NCT03547973) which aims to evaluate the effectiveness of sacituzumab govitecan (SG) in treating metastatic urothelial carcinomas that had previously been treated with platinum-based chemotherapy and checkpoint inhibitors. SG recognizes Trop-2, a transmembrane glycoprotein which is overly expressed in many carcinomas. The results are quite promising, with a median PFS of 5.4 months and an ORR of 27%. He also states that research is being conducted into using pembrolizumab alongside SG for enhanced ORR. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).